Wall Street Zen Upgrades Femasys (NASDAQ:FEMY) to “Hold”

Femasys (NASDAQ:FEMY) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other brokerages also recently issued reports on FEMY. Laidlaw initiated coverage on shares of Femasys in a research report on Thursday, November 20th. They set a “buy” rating and a $6.50 price objective on the stock. Lake Street Capital assumed coverage on shares of Femasys in a report on Tuesday, March 3rd. They issued a “buy” rating and a $1.50 target price for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Femasys in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $5.50.

Femasys Stock Performance

Shares of Femasys stock opened at $0.53 on Friday. The firm’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $0.62. The stock has a market capitalization of $30.99 million, a price-to-earnings ratio of -0.74 and a beta of -2.53. Femasys has a 12 month low of $0.31 and a 12 month high of $1.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.16 and a quick ratio of 0.61.

Hedge Funds Weigh In On Femasys

Large investors have recently bought and sold shares of the company. Cetera Investment Advisers acquired a new stake in shares of Femasys in the 4th quarter worth $36,000. Kovack Advisors Inc. acquired a new position in shares of Femasys during the fourth quarter worth about $27,000. State Street Corp raised its holdings in Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares in the last quarter. Jane Street Group LLC purchased a new position in Femasys during the fourth quarter worth about $62,000. Finally, HRT Financial LP acquired a new stake in Femasys in the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.